|
|
|
|
|
|
|
|
|
|
|
|
|
07.11.25 - 13:33
|
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 (GlobeNewswire EN)
|
|
|
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 13:12
|
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,315,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.20 per share, and the pre-funded warrants are being sold at an offering price of $2.199 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions and other expenses payable by Relmada, and excluding the exercise of any pre-funded warrants, are expected to be ...
|
|
|
|
|
|
|
|
|
16.09.25 - 15:03
|
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire EN)
|
|
|
CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the “Listing Rule”)....
|
|
|
10.09.25 - 13:18
|
Relmada Issues Mid-Year CEO Letter to Shareholders (GlobeNewswire EN)
|
|
|
CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today issued a Letter to Shareholders from Sergio Traversa, Chief Executive Officer....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
